MSK-DA01 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04802733
(ClinicalTrials.gov)
May 3, 202112/3/2021Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's DiseasePhase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseBiological: MSK-DA01;Device: MSK-DA01 Cell Delivery DeviceBlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterRecruiting50 Years76 YearsAll12Phase 1United States;Canada